gutflix
GI learning, personalised

Summary

TOFACITINIB RELATED CANCER RISK: RESULTS FROM A SYSTEMATIC REVIEW WITH META-ANALYSIS

Eleonora Alimenti

UEG Week Copenhagen 2023 Poster

IBD

October 15, 2023

A meta-analysis of 26 controlled studies found no difference in overall cancer risk between tofacitinib and placebo or biological drugs, but a slightly higher risk compared to TNF inhibitors.

KEY POINTS

- Tofacitinib is a Janus kinase inhibitor used for immune-mediated inflammatory diseases including rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis, with recent concerns about cancer risk.
- The meta-analysis included 22 articles describing 26 controlled studies (22 randomized controlled trials) from 2047 initial records.
- Compared to any control treatment, tofacitinib showed a relative risk for any cancer of 1.06 (95% CI, 0.86–1.31; p = 0.95).
- Compared to TNF inhibitors specifically, tofacitinib showed a higher overall cancer risk (RR = 1.40; 95% CI, 1.06–2.08; p = 0.02), with significant results for all cancers except non-melanoma skin cancer (RR = 1.47; 95% CI, 1.05–2.06; p = 0.03).
- The authors conclude that further studies are needed to better define the cancer risk of tofacitinib therapy.

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/531602ea-743b-11ee-8935-0242ac140004

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.